Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs M&T Bank Corporation (MTB) Price & Performance

Heron Therapeutics IncTrade
M&T Bank CorporationTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs M&T Bank Corporation — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $61.47M), while M&T Bank Corporation trades at $252.54 (market cap $36.42B). The key difference: M&T Bank Corporation is far larger — about 592.5× Heron Therapeutics Inc's market cap, and M&T Bank Corporation pays a 2.38% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

HRTXMTB
Market Cap
$61.47M$36.42B
Sector
HealthFinancials
52-Week High
$1.49$254.04
52-Week Low
$0.32$178.63
Enterprise Value
$168.21M
Dividend Yield
2.38%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.

The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.

M&T Bank Corporation

M&T Bank (MTB) trades at $252.73, up 0.64% on the day, with a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings expectations in recent quarters, including Q2 2026 EPS of $5.35 versus $4.66 expected. Revenue growth and net interest income expansion support a solid profit margin of 30.85% for 2026. Analyst sentiment is mixed but leans positive, with a consensus price target of $255.92.

The outlook for MTB remains favorable due to robust earnings momentum and operational efficiency, though risks include potential interest rate volatility and competitive pressures in regional banking. The stock's current valuation at a P/E of 13.35 offers reasonable upside relative to peers, making it an attractive hold for investors seeking steady dividend income and growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About M&T Bank Corporation

M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.

Read more on MTB